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ferences in the appropriate prescribing of tegaserod in patients
whose plan required PA (n = 998) compared with patients whose
plans did not require PA (n = 1640) (94.1% vs 93.4%, respec-
tively, p = 0.45). CONCLUSIONS: Most patients receiving
tegaserod had a diagnostic claim for IBS or one of its cardinal
symptoms (abdominal pain, bloating, or constipation), indicat-
ing that tegaserod is being prescribed appropriately. Moreover,
our analysis revealed that PA for tegaserod did not have an effect
on appropriate GI prescribing, thus bringing into question the
value of PA.
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OBJECTIVES: to examine the utilization trends of gastric acid-
suppressive drugs, including Proton Pump Inhibitors (PPIs) and
Histamine-2 Receptor Inhibitors (H2RAs) between 1995 and
2005. METHODS: Patient records and prescription records
were analyzed for patients enrolled in the General Practice
Research Database in the UK. The prevalence of PPIs and
H2RAs use from 1995 to 2005 were compared. The average
number of prescriptions per person per month was calculated for
users of PPIs and H2RAs, respectively. Age and gender of users
of PPIs and H2RAs were compared between 1995 and 2005.
RESULTS: One-year prevalence of PPIs use increased from 33.5
per 1000 persons in 1995 to 52.2 per 1000 in 2005. Alterna-
tively, one-year prevalence of H2RAs use decreased from 53.0
per 1000 in 1995 to 13.1 per 1000 in 2005. In 1995, the average
monthly number of H2RAs prescriptions was 0.34 (SE = 0.32),
and the monthly number of PPIs prescriptions was 0.35 (SE =
0.33). In 2005, monthly mean number of H2RAs prescriptions
was 0.34 (SE = 0.35), and the monthly number of PPIs pre-
scriptions was 0.42 (SE = 0.40). The number of PPIs prescrip-
tions is signiﬁcantly higher in 2005 than that in 1995 (P < 0.01).
From 1995 to 2005, the mean age of PPIs users decreased from
69.0(SE = 16.9) to 61.8(SE = 17.3) and the mean age of H2RAs
users decreased from 68.7 (SE = 12.7) to 60.0(SE = 19.6) 
(p < 0.01 for both PPIs and H2RAs). The proportion of users
less than 60 years old signiﬁcantly increased from 1995 to 2005
(p < 0.01 for PPIs and H2RAs). CONCLUSION: In the general
practice setting of UK, the annual prevalence of PPI use increased
with reduced prevalence of H2RA use in the past decade. The
monthly number of prescription of PPIs signiﬁcantly increased
from 1995 to 2005. Users of gastric-acid suppressive drugs
trended younger over time. The economic and epidemiologic
impact of this trend needs to be studied further.
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OBJECTIVES: Determine the changes in utilization of physician,
emergency department, and hospital outpatient services related
to constipation and Irritable Bowel Syndrome (IBS) over the past
10 years. METHODS: This study was a retrospective analysis 
of the National Ambulatory Medical Care Survey (NAMCS) 
and the National Hospital Ambulatory Medical Care Survey
(NHAMCS) from 1993–2003. The NAMCS and NHAMCS are
national probability surveys of visits to ofﬁce-based physicians
and ambulatory services in hospital emergency and outpatient
departments. Constipation visits were identiﬁed based on a
reason for visit or a diagnosis of constipation (ICD-9-CM =
564.0). IBS visits were identiﬁed based on a diagnosis of IBS
(ICD-9-CM = 564.1) or a prescription for alosetron or tegaserod.
Sensitivity analyses were performed to explore the impact of
various case deﬁnitions. RESULTS: In 2003, 8.81 million
(95%CI: 6.73 million–10.90 million) visits were related to con-
stipation, 7.04 million physician ofﬁce visits, 1.15 million emer-
gency department visits, and 0.63 million outpatient hospital
department visits—representing over a 400% increase compared
to the 2.20 million total visits made in 1993. In 2003, 67.0% of
visits were made by females, 20.9% by those less than 10 years
old, and 38.5% by those 65 and older, and 11.0% by blacks.
There were over 3.53 million IBS related visits in 2003 which is
16% higher than the 2.97 million visits in 1995. In 2003, 92.0%
of visits were made by females, 30.0% were made by persons
between 25–44 years of age, and 9.0% were made by blacks.
CONCLUSIONS: Over the past ten years, ambulatory visits to
treat constipation have increased dramatically across all regions
of the country, races, and ages, but have particularly increased
for infants and children. Over a similar time period, IBS visits
have remained relatively stable but represent a sizable reason
persons, particularly women, contact the U.S. ambulatory care
setting.
GI DISORDERS—Methods and Concepts
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OBJECTIVES: Previous literature reported patients with GERD
have $240 more in medical care costs compared with patients
without GERD (JMCM 2003;7:6–13). However, no data exist
to differentiate these costs by symptom severity. This study’s
purpose was to assess utilization and costs associated with mild,
moderate, and severe GERD-related symptoms using a new
approach. METHODS: An Internet-based survey of US adults
was conducted using GERD Symptom & Medication Question-
naire (GERD-SMQ), a validated screening tool. Severity of heart-
burn and acid regurgitation symptoms were rated on a 10-point
scale. The highest rating value of heartburn and acid regurgita-
tion was used. Respondents were classiﬁed into the following
severity strata: mild (1–4), moderate (5–7), and severe (8–10).
Subjects were asked to report the frequency of hospitalizations,
emergency room visits, physician ofﬁce visits, tests, and proce-
dures relating to GERD over the past six months. Utilization 
of each component was converted into monetary value using
publicly available fee schedules. Imputed costs for each severity
stratum were summed and divided by the average total imputed
cost among all cases to determine the utilization weights relative
to the “average” GERD case. Utilization weights were multiplied
by $240 to estimate cost for each severity stratum. RESULTS: A
total of 701 GERD cases were identiﬁed: 22.1%, 48.6%, and
24.0% were categorized as mild, moderate, and severe and the
remaining 5.3% as having no active symptoms. Compared with
“average” GERD cases, patients classiﬁed as having mild, mod-
erate, and severe GERD-related symptoms had relative utiliza-
tion weights of 0.404, 0.610, and 2.458 respectively, and
GERD-attributable costs of $97, $146, and $590 per year
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respectively. CONCLUSIONS: Self-reported utilization can 
be used to differentiate costs across severity strata in GERD 
sufferers. This information is useful for modeling the economic
consequences of reducing GERD-related severity and may 
be applicable to other conditions when published data are
incomplete.
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OBJECTIVE: Results from studies using patient-reported data
in employed populations indicate that Gastroesophageal Reﬂux
Disease (GERD) causes a reduction in productivity while at work
of around 10%. The aim of this study was to assess if a link
between GERD and reduced productivity while at work can be
established by using objective measurements of hourly and
annual at-work productivity. METHODS: We examined the
Human Capital Management Services Research Reference data-
base of employees where units-of-production are captured on a
per-employee-per-day basis. ICD-9 Codes were used to distin-
guish employees with GERD from the non-GERD cohort. The
index date in the GERD cohort was deﬁned as the date of ﬁrst
diagnosis during 2001 or later, while the average GERD index
date was used in the non-GERD cohort. Hourly and annual 
productivity were measured during the year following each
employee’s index date. Regression modelling was used to
measure the productivity differences between employees with
GERD and employees without GERD while controlling for age,
marital status, race, full-time/part-time status, location, and
comorbidity (Charlson Comorbidity Index). RESULTS: Data
were available for 27,316 employees: 541 employees with GERD
and a control group of 26,775 employees without GERD. The
mean age of employees with GERD was 40 years, and 77% were
full time employees. The analysis of at-work productivity show
that GERD employees’ average units processed were signiﬁcantly
lower by 4.4% hourly and 6.0% annually (P < 0.05). CON-
CLUSIONS: Even though quality aspects of work productivity
are not captured, objective productivity measurements from real
work-output data (the number of units of work performed by
each employee on a daily basis) show that GERD has a signiﬁ-
cant impact on productivity while at work. Interventions focused
on managing GERD could increase work productivity and thus
lead to beneﬁts for the employee, the employer and society as a
whole.
GI DISORDERS—Patient Reported Outcomes
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OBJECTIVES: According to previous data only 30% to 60% of
patients with inﬂammatory bowel disease (IBD) take their med-
ication as prescribed. While objective predictors of nonadherence
are relatively well studied, there is little data regarding what IBD
patients think about their medications and their reasons for non-
adherence. METHODS: A total of 22 consecutive patients with
IBD from the University of Maryland Inﬂammatory Bowel
Disease Program were interviewed. We collected data on the
patients’ sociodemographic proﬁle, their medications, and asked
them to complete the Medication Attitude Survey (MAS). The
MAS has 24 questions asking why patients may incorrectly take
their medications. The nonadherence reasons were identiﬁed
from a literature review. RESULTS: Fifteen patients were female
(68.2%), and the average age was 37.4 ± 13 years. Ten patients
had Crohn’s disease (45.5%), 6 had ulcerative colitis (27.3%),
and 5 had indeterminate colitis (22.7%). Most of the patients
(90.9%) selected at least one reason for nonadherence. The main
reasons (selected by more than 25% of patients) were “I forget
to take my medication”(72.7% of patients), “I feel better”
(40.9%), “My medications are too expensive” and “I feel very
bad”(both 36.6%), “I want to avoid side effects” and “I want
to feel healthy” (both 31.8%), “I want to forget about my
disease” and “I think that the prescribed dose of my medication
is too much” (both 27.3%). The sets of reasons were different
for adherent and nonadherent patients (the degree of nonadher-
ence was assessed using patient self-report). The MAS has shown
good initial psychometric properties with Cronbach Alpha 0.91
and mean inter-item correlations 0.32. CONCLUSIONS: The
identiﬁed reasons for patient nonadherence suggest that patient
education and other interventions are needed to increase 
medication adherence. The scale used in the study can be useful
in routine clinical practice to identify possible problems with
patient adherence.
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OBJECTIVE: The medical literature points out the adherence
and ribavirin dose as important factors to achieve the best results
in the CHC treatment. In Brazil, the government set local assisted
administration centers (LAAC) to provide the drugs and admin-
ister the interferons (conventional and peguilated) to the patients
in order to improve these factors. The objective of this study is
to evaluate the adherence to the CHC treatment with peguin-
terferon and conventional interferon and the actual dose of rib-
avirin administered to the patients, in Brazil. METHODS: Thirty
physicians in south, southwest and Midwest regions of Brazil
performed a prospective cross sectional evaluation. They used a
structured questionnaire with the speciﬁc questions. RESULTS:
A total of 656 patients were evaluated during 2 months. The
average age was 44 years and the mean body weight was 
70.5kg. According to the BMI, 50% of the patients are over-
weight or obese. The adherence to treatment was calculated as
the rate between the prescribed doses and doses actually taken.
79.7% of the patients was 100% adherent. Only 60.8% of the
patients was 100% adherent to conventional interferon. 84.6%
of the patients were 100% adherent to peginterferon alfa 2 a and
86.8% of the patients were 100% adherent to peginterferon 
alfa 2b. LAAC patients adherence (100%) is greater than the
patients that apply the treatment (interferons) at home (84.8%
vs. 71.1%). 93.4% of the Brazilian patients receive 1g per day
or more of ribavirin. Given that the mean weight of the Brazil-
ian patient is 70.5kg the majority of the patients receive more
than 10.6mg/kg of ribavirin. CONCLUSIONS: The median
weight of the Brazilian patients is 70.5kg. More than 90% 
of the patients are receiving 1g per day or more of ribavirin.
LAAC appear to directly affect the adherence to the treatment,
improving it.
